1. De Lomhaert S, Chatelain RE, Fink CA, Trapani AJ (1996) Design and pharmacology of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Curr Pharma Design 2: 443 – 462
2. Fink CA (1996) Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Expert Opin Ther Patents 6: 1147-1164; Robl JA, Ryono DE (1999) Recent advances in the design and development of vasopeptidase inhibitors. Expert Opin Ther Patents 9: 1665 – 1677
3. Kenny AJ, Stephenson SL (1988) Role of endopeptidase 24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett 232: 1 – 8
4. Sonnenberg JL, Sakane Y, Jeng AY, Koehn JA, Ansell JA, Wennogle LP, Ghai RD (1988) Identification of protease NEP 24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 9: 173 – 180
5. Winquist RJ, Hintze TH (1990) Mechanism of atrial natriuretic factor-induced vasodilatation. Pharmacol Ther 48: 417 – 426